The Presence of Type 12 M-Protein Antigen in Group G Streptococci

By W. R. MAXTED

Cross-Infection Reference Laboratory, Central Public Health Laboratory, Colindale, London, N.W. 9

AND ELIZABETH V. POTTER
Northwestern University, Chicago, Illinois, U.S.A.

(Accepted for publication 19 April 1967)

SUMMARY

Three strains of group G streptococci isolated from a community in which glomerulonephritis is common were found to have an M-protein antigen indistinguishable from the type 12 M-protein of group A, type 12, streptococci.

INTRODUCTION

The M-antigen of *Streptococcus pyogenes* (the group A streptococcus) is an essential factor in the virulence of the organism as indicated by its ability to kill mice and to multiply in human blood; and antibodies to M-protein form the basis of type-specific immunity (Lancefield, 1962). Other protein antigens, such as the T and R antigens, which are commonly present in *S. pyogenes*, may also be found in streptococci of other Lancefield groups (Lancefield & Dole, 1946; Crowley, 1944; Maxted, 1949, 1953). The M-proteins, however, are generally believed to occur only in members of Lancefield group A and in variants of that group which have lost their A-carbohydrate (Wilson, 1945; McCarty & Lancefield, 1955).

During the bacteriological investigation of a large epidemic of acute glomerulonephritis in Trinidad in 1965 (Simon *et al.* 1965), three strains of group G streptococci were isolated which appeared to possess the group A, type 12, M-protein. These three cultures formed part of a collection of streptococci of groups A, C and G isolated by one of us (E.P.) from patients with glomerulonephritis and from non-nephritic school children. The laboratory in Chicago found that one of the group G streptococci gave a strong precipitin reaction with M 12 antiserum. The M 12 antigen in this strain and in the other two cultures described in this report was detected independently at Colindale during an investigation into the specificity of a highly absorbed fluorescent conjugate of group A, type 12, antiserum (Heimer, 1966). Subsequently, two additional strains have been isolated and identified in Chicago. Because of the association with acute glomerulonephritis of group A streptococci which possess the M 12 antigen (Rammelkamp & Weaver, 1952; Wilmers, Cunliffe & Williams, 1954), it was of some importance to establish precisely the nature of the antigen present in these group G streptococci.
METHODS

Streptococci. Group G strains. Culture no. 2832 was isolated from the throat of a child with acute glomerulonephritis in San Fernando General Hospital, Trinidad. (A group A streptococcus, with no detectable M-antigen, but with the T-agglutination pattern 3/13, B 3264, was isolated from a skin sore of the same patient.) Cultures 2439 and 2440 were isolated from skin sores of children without nephritis during a school survey also in the San Fernando area. These three organisms had the type 12 antigen and will be referred to as G 12.

Group A strains. Culture no. 1077 was a type 12 laboratory strain originally isolated from a case of glomerulonephritis. Culture no. 41448 was a mouse-virulent laboratory strain, also of type 12, originally isolated from a case of scarlet fever. Strain NCTC 8305 (type 24) was used as a control in bactericidal tests.

Media. A modified Todd-Hewitt broth was used; it was a meat infusion with buffer and glucose added, and the whole sterilized by heat.

Blood agar was Hartley digest agar + 7% (v/v) horse blood.

Bactericidal tests. Streptococci capable of multiplying in heparinized normal human blood are killed when small amounts of type-specific antiserum containing M-antibody are added. The test used here was essentially that described by Maxted (1956), except that the mixtures were rotated end-over-end at 37° and 0.02 ml. samples inoculated into blood agar pour plates after 3-4 hr.

Antisera. These were made by injecting rabbits intravenously with washed whole-cell vaccines made by concentrating 18 hr broth cultures tenfold and heating them to 60° for 1 hr. A 1 ml. dose of this vaccine was given intravenously on two successive days each week for 8 weeks.

Antigen extracts. The overnight growth from 50 ml. of broth was extracted with 0.6 ml. 0.2N-HCl in boiling water for 10 min., cooled, neutralized with 0.2N-NaOH and centrifuged until clear.

Precipitin tests were done in capillary tubes by the method first described by Swift, Wilson & Lancefield (1943).

Absorption of sera. For absorption with whole organisms, equal volumes of packed bacteria and serum were mixed, left for 4 hr at 37°, and then centrifuged until clear.

Absorption with extracted antigen was done as follows. Four volumes of ethanol (95%, v/v in water) were added to 1 volume of antigen extract. After centrifugation, the supernatant fluid was removed and the precipitate taken up in 1 volume of serum. The mixture was left at 37° for 2 hr and then at 4° overnight before centrifuging until clear.

Double gel-diffusion. Five ml. of 1% (w/v) 'Oxoid' Ionagar No. 2 in water at pH 7.4 was poured into Petri dishes of 2 in. diameter. Wells 4 mm. in diameter were arranged radially 5 mm. from a centre well.

Mouse-protection tests. White mice (18–20 g.) were given 0.25 ml. of serum intraperitoneally and challenged 24 hr later with 0.5 ml. of a 16 hr broth culture suitably diluted in saline with 10% (v/v) of broth added.

Fluorescent staining. Smears were made directly from 16 hr blood agar plate cultures, stained with a highly specific fluorescent conjugate of a group A, type 12, antiserum, and examined microscopically with illumination from a Mazda ME/D 250 W. mercury vapour lamp and a chance Pilkington O.X.1 excitation filter with an Ilford 805 Q barrier filter.
RESULTS

Capillary precipitin tests were done with acid extracts of the three group G strains and all the M-antisera for *Streptococcus pyogenes* types available at Colindale (types 1—3, 5, 6, 9, 11, 12, 14, 15, 17—19, 22—26, 29—31, 33, 36, 37, 39, 41, 43, 46—51). All three precipitated with type 12 antiserum and with no other.

The extracted antigen from the group G strain 2832 was precipitated with ethanol and used to absorb a sample of group A, type 12, M-antiserum made with strain 1077. The serum before and after absorption was tested against an acid extract of strain 1077. The antigen from the group G strain completely removed the type 12 precipitating antibody from the serum (Table 1).

Table 1. *Removal of precipitating antibody, and of bactericidal power from a streptococcus group A, type 12, by absorption with streptococcus group G, type 12, protein*

<table>
<thead>
<tr>
<th>Streptococcal strain</th>
<th>Group A, type 12</th>
<th>Inoculum total colony count</th>
<th>Colony count in 0.02 ml. sample after 3 hr incubation with serum</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Group A, type 12, absorbed with G12 protein</td>
<td>Normal rabbit</td>
<td>Group A, type 12, absorbed with G12 protein</td>
</tr>
<tr>
<td>1077, group A, type 12</td>
<td>++</td>
<td>40</td>
<td>80</td>
</tr>
<tr>
<td></td>
<td></td>
<td>400</td>
<td>T.N.C.*</td>
</tr>
<tr>
<td>8305, group A, type 24</td>
<td>—</td>
<td>55</td>
<td>180</td>
</tr>
<tr>
<td></td>
<td></td>
<td>550</td>
<td>T.N.C.</td>
</tr>
</tbody>
</table>

*T.N.C. = Colonies too numerous to count.*

If this were a true M-antigen-antibody system, the bactericidal power of the serum, when added to normal human blood, should also be removed by the group G extract. Normal rabbit serum and group A, type 12, antiserum, before and after absorption with G12 antigen, were each mixed with samples of heparinized normal human blood, and the killing efficiency of these mixtures tested against group A, type 12, streptococci. The bactericidal power of the group A, type 12, serum was removed by absorption with the G12 antigen from strain 2832 (Table 1). The group A, type 24, strain used as control grew unrestrictedly in all blood + serum mixtures.

The three group G12 strains were each used as inocula in bactericidal tests with similar blood + serum mixtures and proved equally susceptible to the killing efficiency of group A, type 12, antiserum.

Antisera were made against each of the three group G, type 12, strains and tested for precipitating antibody against stock M-extracts of all known types of group A streptococci. The group A, type 12, extract reacted well with each of these sera, but no extract of any other type gave a similar precipitate. The sera were also tested for their bactericidal power against a group A, type 12, strain, a group A, type 24, strain, and also against each of the group G vaccine strains. The bactericidal action of two of
the antisera against the A12 and each of the G12 strains was good. The third antiserum, 
made against strain 2832, was not so bactericidal, but showed some bacteriostatic effect. 
The results were reproducible with blood from several donors; one such test is shown 
in Table 2. In this test a single inoculum of each test strain was used throughout. 

It was possible that the group G strains might have two M-protein antigens, the A12 
and another found only among group G strains. If this were so, and the group G coccii 
surviving in the bactericidal system did so because they possessed this second antigen, 
a mixture of the group A, type 12, antigen and the G12 antiserum in a single bacteri-
cidal system might be expected to give greater killing. Bactericidal tests done with such 
a mixture of antisera showed no greater killing than with either antiserum alone.

Table 2. A comparison of the bactericidal power of streptococcus group A, type 12, 
antiserum and antisera prepared against streptococcus group G, type 12, strains

All samples received a single inoculum of the strain tested. This was 0.02 ml. of an 18 hr culture 
diluted 10⁻⁴ and averaged 200–300 organisms for each strain.

<table>
<thead>
<tr>
<th>Streptococcus</th>
<th>Antisera made with strains</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Normal rabbit serum</td>
</tr>
<tr>
<td></td>
<td>Group and type</td>
</tr>
<tr>
<td></td>
<td>A12</td>
</tr>
<tr>
<td></td>
<td>2439</td>
</tr>
<tr>
<td></td>
<td>2440</td>
</tr>
<tr>
<td></td>
<td>2832</td>
</tr>
<tr>
<td></td>
<td>1077</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Colony numbers</th>
<th>T.N.C.*</th>
</tr>
</thead>
<tbody>
<tr>
<td>41448 A12</td>
<td>31</td>
</tr>
<tr>
<td>217D A24</td>
<td>T.N.C.</td>
</tr>
<tr>
<td>2439 G12</td>
<td>64</td>
</tr>
<tr>
<td>2440 G12</td>
<td>40</td>
</tr>
<tr>
<td>2832 G12</td>
<td>46</td>
</tr>
<tr>
<td>1077 A12</td>
<td>2</td>
</tr>
</tbody>
</table>

* T.N.C.: colonies too numerous to count.

Gel-diffusion tests were done to show the identity of the type antigens of the group G 
and group A organisms. With group G, type 12, antiserum in the centre well and 
extracts of the A12 and G12 strains in the peripheral wells a strong and continuous 
line of identity was seen. When each of the G12 antisera was tested in the centre well 
against similar extracts, a continuous line of identity was again seen, as well as several 
other lines of precipitation with the G12 extracts (probably due to the group antibody, 
since these antisera were unabsorbed).

It has been shown repeatedly that anti-M sera, when injected into mice, give excellent 
passive protection against a subsequent challenge with a virulent group A streptococcus 
of homologous type. Antiseras against the G12 strains should therefore protect mice 
challenged with group A, type 12, streptococci. The group A and the group G antiseras 
were tested against strain 41448 (group A, type 12). Mice in groups of 20 were each 
given 0.25 ml. of antiserum intraperitoneally 18 hr before the inoculation of the 
virulent streptococci. The test was done with two dilutions of the challenge strain. The 
G12 antisera protected mice as effectively as the group A, type 12, antiserum against 
fatal infection with the virulent group A, type 12, streptococci. The results of a repre-
sentative test with one G12 serum are shown in Table 3.

Because of the widely held belief that M-antigens are to be found only in group A 
streptococci, they have probably not been looked for extensively in members of other 
groups. A survey was therefore made of a larger number of group G strains, both from
stock and freshly isolated, including many from Trinidad. The fluorescent staining, which had proved so sensitive and successful originally, was used as a screening test on 140 group G and 10 group C strains. Thirty-seven of the group G and three of the group C strains, all isolated in Trinidad, were also extracted with acid and tested by the capillary precipitin test against all the available group A anti-M sera. No other strains were found which showed any relationship with group A organisms.

Table 3. The ability of streptococcus group A, type 12, antiserum and antiserum made against a streptococcus group G, type 12, strain (2440) to protect mice challenged with a virulent group A, type 12, streptococcus

Challenge doses. One-half ml. of 16 hr broth culture diluted in saline +10% (v/v) broth. One-half ml. of a 10⁻⁸ dilution of culture contained approximately 750 organisms.

<table>
<thead>
<tr>
<th>Serum used for protection</th>
<th>Dose of challenging strain 41448 type 12 (dilution)</th>
<th>Time after challenge (days)</th>
<th>Total deaths</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal rabbit</td>
<td>10⁻⁵</td>
<td>1 1 2 4 0 0 1 0 0</td>
<td>24/40</td>
</tr>
<tr>
<td></td>
<td>10⁻⁸</td>
<td>1 3 1 0 0 0 0 0 0</td>
<td></td>
</tr>
<tr>
<td>Group G, type 12</td>
<td>10⁻⁶</td>
<td>0 0 0 1 0 0 0 0 0 0</td>
<td>4/40</td>
</tr>
<tr>
<td>(strain 2440)</td>
<td>10⁻⁸</td>
<td>0 0 3 0 0 0 0 0 0 0</td>
<td></td>
</tr>
<tr>
<td>Group A, type 12</td>
<td>10⁻⁶</td>
<td>0 0 0 0 0 0 0 0 0 0</td>
<td>3/40</td>
</tr>
<tr>
<td>(strain 1077)</td>
<td>10⁻⁸</td>
<td>0 0 1 1 0 0 0 0 0 0</td>
<td></td>
</tr>
</tbody>
</table>

Experiments were made to see whether the G12 strains were in fact group A strains with the unusual ability of synthesizing group G cell-wall or were true group G strains which formed type 12 M-protein.

(1) A cell-wall analysis of the three G12 strains, kindly done by Mr G. Colman by the techniques applied by him to a large variety of streptococci (see Colman & Williams, 1965) showed the presence of galactosamine and galactose, both characteristic of the group G streptococcal cell-wall but not found in group A streptococci.

(2) The phage-associated lysin (Maxted, 1957; Krause, 1958) which attacks the cell-wall of viable group A streptococci did not lyse the three G12 strains.

(3) Group A strains resistant to bacitracin in the 'differentiation' disc test (Maxted, 1953) are, in our experience, very rare. All three of the G12 strains were resistant to bacitracin.

(4) In an extensive experience of routine serological typing of Streptococcus pyogenes, we have found that organisms with the M12 antigen are nearly always agglutinated by antisera prepared against the T antigen of type 12 or type 10. Suspensions of the G12 strains were not agglutinated by antisera containing the T antibodies of type 12 or type 10.

(5) Virulent and temperate phages which had been propagated on group A, type 12, streptococci and shown to be active on the majority of group A strains of type 12, did not lyse any of the three group G, type 12, strains.

DISCUSSION

The evidence presented here suggests that strains 2832, 2439 and 2440 belong to Lancefield group G, but have the ability to synthesize type 12 M-antigen. It now seems
possible that an infection with these or similar group G streptococci might result in the production of protective antibody against certain members of group A, a possibility which had not previously seemed to need consideration. The ability of these group G strains to establish an infection is, however, uncertain. Two of the strains were isolated from skin lesions, but there is no certainty that they were the cause of them, since the presence of two or more different streptococci in the skin lesion of the same patient is not uncommon (Barrow, 1961; Dr D. J. C. Bassett, personal communication; Anthony, Perlman & Wannamaker, 1967). The third strain was isolated from the throat of a patient suffering from glomerulonephritis, but a group A streptococcus was isolated concurrently from a skin lesion. There is no conclusive evidence that the M-antigen of the group A, type 12, streptococcus is responsible for its ability to cause glomerulonephritis. The possibility cannot be excluded, however, that the nephritogenic factor might be associated closely with the type 12 antigen either in Streptococcus pyogenes or in some other group of streptococci. The significance of these findings will remain uncertain until more is known about the ability of the various strains of S. pyogenes isolated in Trinidad to cause glomerulonephritis. It is certain, however, that group G streptococci with the M12 antigen form only a tiny minority of the streptococcal strains to be found in skin lesions and in the respiratory tract in Trinidad, and it is therefore unlikely that they are a common cause of either impetigo or glomerulonephritis. Their ability to multiply in whole human blood suggests, however, that they may be potentially virulent for man.

The G12 organisms may prove useful in genetic studies of streptococci, but it is not yet possible to speculate about their origin. In general, it is our experience that strains of Streptococcus pyogenes showing undoubted evidence of M12 antigen are rarely isolated in Trinidad. At the Colindale laboratory we have recently examined serologically over 1000 cultures of S. pyogenes from Trinidad and did not find the M12 antigen in any of them. Several were agglutinated by the T12 antiserum, but they formed only a small minority of the strains isolated from cases of glomerulonephritis. Although we made a search for M-antigens among group G strains, the survey was a small one and was mainly for type 12 M-antigen, but there is no reason why M-antigens of other types should not be found. A more extensive search for M-antigens in streptococci of other Lancefield groups might be rewarding.

One of us (E. P.) received support for part of this study from grant no. USPHS 358 5 ROI HE 07057-04.

REFERENCES


12 M-protein in group G streptococci


